Touboul E, Béral H M, Raphaël M, Buscaill A, Dominique S, Guérin R A
Bull Cancer. 1987;74(2):159-65.
Nine patients, aged 19 to 57 years (mean: 37 years) with non hodgkin lymphoma (NHL) secondarily resistant to chemotherapy (8 stages CS IV involving the bone marrow and 1 stage III) were studied. Histologic forms according to the Lennert classification were as follow: 1 nodular centrocytic which developed into a diffuse centroblastic, 3 diffuse immunoblastic, 4 diffuse centrocytic-centroblastic, and 1 T cell lymphoblastic. The nine patients were managed by external irradiation of the lower half of the body (LHBI), followed six weeks later by irradiation of the upper half of the body (UHBI). A single dose of 8.00 Gy in 7 cases and 6.00 Gy in 2 cases was delivered. Three patients developed severe medullary aplasia. Each of these patients had received 8.00 Gy and been given a course of chemotherapy between the two radiation sessions. The aplasia was fatal in two patients. Overall apparent clinical remission rate was 5/9, with one iatrogenic death at 3.5 months; one lost to follow-up after 8 months; for three other cases, the duration of apparent complete remission was 15, 22 and 36 months. One patient was alive in partial remission 30 months after irradiation. Three patients who failed to respond to treatment, were died between 4 and 11 months.
对9例年龄在19至57岁（平均37岁）的非霍奇金淋巴瘤（NHL）患者进行了研究，这些患者对化疗继发耐药（8例为CS IV期累及骨髓，1例为III期）。根据Lennert分类，组织学类型如下：1例结节性中心细胞型，后来发展为弥漫性中心母细胞型；3例弥漫性免疫母细胞型；4例弥漫性中心细胞-中心母细胞型；1例T细胞淋巴母细胞型。这9例患者接受了下半身体外照射（LHBI），六周后进行上半身照射（UHBI）。7例给予单次剂量8.00 Gy，2例给予6.00 Gy。3例患者出现严重骨髓再生障碍。这些患者均接受了8.00 Gy照射，并在两次放疗期间接受了一个疗程的化疗。其中2例患者的再生障碍导致死亡。总体明显临床缓解率为5/9，1例在3.5个月时出现医源性死亡；1例在8个月后失访；另外3例患者，明显完全缓解持续时间分别为15、22和36个月。1例患者在放疗后30个月存活，处于部分缓解状态。3例治疗无效的患者在4至11个月之间死亡。
